PKTX Stock Overview
ProtoKinetix, Incorporated, a research and development stage bio-technology company, focuses on the scientific medical research of anti-freeze glycoproteins (AFGPs) or anti-aging glycoproteins (AAGPs).
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
ProtoKinetix, Incorporated Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.03 |
| 52 Week High | US$0.083 |
| 52 Week Low | US$0.018 |
| Beta | 0.12 |
| 1 Month Change | -9.09% |
| 3 Month Change | -15.61% |
| 1 Year Change | -55.88% |
| 3 Year Change | -83.33% |
| 5 Year Change | -53.16% |
| Change since IPO | 650.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| PKTX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 0.7% | 2.3% |
| 1Y | -55.9% | 7.1% | -9.7% |
Return vs Industry: PKTX underperformed the US Biotechs industry which returned 7.1% over the past year.
Return vs Market: PKTX underperformed the US Market which returned -9.7% over the past year.
Price Volatility
| PKTX volatility | |
|---|---|
| PKTX Average Weekly Movement | 25.3% |
| Biotechs Industry Average Movement | 12.2% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: PKTX is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 25% a week.
Volatility Over Time: PKTX's weekly volatility (25%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | n/a | Clarence Smith | https://www.protokinetix.com |
ProtoKinetix, Incorporated, a research and development stage bio-technology company, focuses on the scientific medical research of anti-freeze glycoproteins (AFGPs) or anti-aging glycoproteins (AAGPs). The company’s AFGPs have commercial applications primarily in health care solutions. It develops AAGP to treat dry-eye diseases.
ProtoKinetix, Incorporated Fundamentals Summary
| PKTX fundamental statistics | |
|---|---|
| Market Cap | US$9.69m |
| Earnings (TTM) | -US$1.72m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-5.6x
P/E RatioIs PKTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PKTX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$1.72m |
| Earnings | -US$1.72m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0053 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did PKTX perform over the long term?
See historical performance and comparison